全文获取类型
收费全文 | 64852篇 |
免费 | 5097篇 |
国内免费 | 654篇 |
出版年
2023年 | 254篇 |
2022年 | 823篇 |
2021年 | 1345篇 |
2020年 | 854篇 |
2019年 | 1047篇 |
2018年 | 1445篇 |
2017年 | 1222篇 |
2016年 | 1982篇 |
2015年 | 3158篇 |
2014年 | 3580篇 |
2013年 | 4094篇 |
2012年 | 5195篇 |
2011年 | 5048篇 |
2010年 | 3201篇 |
2009年 | 2822篇 |
2008年 | 3887篇 |
2007年 | 3731篇 |
2006年 | 3310篇 |
2005年 | 3091篇 |
2004年 | 2820篇 |
2003年 | 2486篇 |
2002年 | 2188篇 |
2001年 | 1811篇 |
2000年 | 1684篇 |
1999年 | 1406篇 |
1998年 | 597篇 |
1997年 | 534篇 |
1996年 | 423篇 |
1995年 | 370篇 |
1994年 | 352篇 |
1993年 | 289篇 |
1992年 | 566篇 |
1991年 | 535篇 |
1990年 | 462篇 |
1989年 | 438篇 |
1988年 | 361篇 |
1987年 | 314篇 |
1986年 | 274篇 |
1985年 | 273篇 |
1984年 | 203篇 |
1983年 | 182篇 |
1982年 | 153篇 |
1981年 | 150篇 |
1979年 | 178篇 |
1978年 | 142篇 |
1977年 | 120篇 |
1976年 | 111篇 |
1975年 | 130篇 |
1974年 | 151篇 |
1973年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
51.
52.
53.
Yu-Chi Su Goutham Venkata Naga Davuluri Cheng-Hao Chen Dong-Che Shiau Chien-Chin Chen Chia-Ling Chen Yee-Shin Lin Chih-Peng Chang 《PloS one》2016,11(2)
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients and promotes tumor growth by mediating cancer cell adhesion, migration and proliferation, but its role in chemoresistance of HCC is poorly understood. In this study we found that galectin-1 is able to lead to chemoresistance against cisplatin treatment, and subsequent inhibition has reversed the effect of cell death in HCC cells. Moreover, galectin-1 was found to induce autophagic flux in HCC cells. Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells. Increase of mitophagy triggered by galectin-1 was found to reduce the mitochondrial potential loss and apoptosis induced by cisplatin treatment. Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin. Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients. 相似文献
54.
55.
56.
57.
Chung-Te Chang Natalia Bercovich Belinda Loh Stefanie Jonas Elisa Izaurralde 《Nucleic acids research》2014,42(8):5217-5233
The removal of the 5′-cap structure by the decapping enzyme DCP2 and its coactivator DCP1 shuts down translation and exposes the mRNA to 5′-to-3′ exonucleolytic degradation by XRN1. Although yeast DCP1 and DCP2 directly interact, an additional factor, EDC4, promotes DCP1–DCP2 association in metazoan. Here, we elucidate how the human proteins interact to assemble an active decapping complex and how decapped mRNAs are handed over to XRN1. We show that EDC4 serves as a scaffold for complex assembly, providing binding sites for DCP1, DCP2 and XRN1. DCP2 and XRN1 bind simultaneously to the EDC4 C-terminal domain through short linear motifs (SLiMs). Additionally, DCP1 and DCP2 form direct but weak interactions that are facilitated by EDC4. Mutational and functional studies indicate that the docking of DCP1 and DCP2 on the EDC4 scaffold is a critical step for mRNA decapping in vivo. They also revealed a crucial role for a conserved asparagine–arginine containing loop (the NR-loop) in the DCP1 EVH1 domain in DCP2 activation. Our data indicate that DCP2 activation by DCP1 occurs preferentially on the EDC4 scaffold, which may serve to couple DCP2 activation by DCP1 with 5′-to-3′ mRNA degradation by XRN1 in human cells. 相似文献
58.
Hsuan-Hwai Lin Yi-Jen Peng Ming-Jiun Tsai Yi-Ying Wu Tsung-Neng Tsai Hsin-Hung Huang Yu-Lueng Shih Wei-Kuo Chang Tsai-Yuan Hsieh 《Journal of cellular physiology》2020,235(2):1689-1699
Activated hepatic stellate cells promote hepatocellular carcinoma (HCC) progression. Hepatic stellate cells play a key role in retinoid metabolism, and activation of stellate cells increases retinoic acid (RA) in the liver. However, the role of RA in HCC proliferation remains unclear. We aimed to analyse the mechanism of RA in HCC proliferation. Thirty-eight patients who had undergone hepatic resection for HCCs were recruited. Paired non-tumour tissues, adjacent and distal to HCCs, were collected, and the RA levels in the tissues were analysed. The mechanisms of RA and HCC proliferation were assessed in liver cancer cell lines by protein and gene expression analyses. Early recurrence of HCC was significantly higher in patients with a higher RA concentration than in those with a lower RA concentration in tissues adjacent to HCCs (61.1% vs. 20%, p = .010). RA promoted HCC cell proliferation and activated the expression of Amphiregulin, a growth factor in hepatocarcinogenesis. The promoter of Amphiregulin contained the binding sites of the RA receptor, RXRα. Wnt signalling also activated the expression of Amphiregulin, and the RA and Wnt pathways acted synergistically to increase the expression of Amphiregulin. Furthermore, RXRα interacted with β-catenin and then translocated to the nucleus to activate Amphiregulin. An increased RA concentration in the tissues adjacent to the tumour was associated with an early recurrence of HCC. RA activated the expression of Amphiregulin, and then promoted HCC proliferation, which might partly contribute to early recurrence of HCC after hepatic resection. 相似文献
59.
60.
Changsung Kim 《BMB reports》2015,48(5):256-265
Cardiovascular and neurodegenerative diseases are major health threats in many
developed countries. Recently, target tissues derived from human embryonic stem
(hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes
(CMs) or neurons, have been actively mobilized for drug screening. Knowledge of
drug toxicity and efficacy obtained using stem cell-derived tissues could
parallel that obtained from human trials. Furthermore, iPSC disease models could
be advantageous in the development of personalized medicine in various parts of
disease sectors. To obtain the maximum benefit from iPSCs in disease modeling,
researchers are now focusing on aging, maturation, and metabolism to
recapitulate the pathological features seen in patients. Compared to pediatric
disease modeling, adult-onset disease modeling with iPSCs requires proper
maturation for full manifestation of pathological features. Herein, the success
of iPSC technology, focusing on patient-specific drug treatment,
maturation-based disease modeling, and alternative approaches to compensate for
the current limitations of patient iPSC modeling, will be further discussed.
[BMB Reports 2015; 48(5): 256-265] 相似文献